For the quarter ending 2025-12-31, PLUR made $198K in revenue. -$6,543K in net income. Net profit margin of -3304.55%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | 198 | 316 | 358* | 326 |
| Cost of revenues | 112 | 201 | 304* | 126 |
| Gross profit | 86 | 115 | 54* | 200 |
| Research and development expenses | 3,949 | 3,961 | 3,824* | 3,392 |
| Less participation by the national institute of allergy and infectious diseases, or niaid, the israeli innovation authority, or iia, and horizon europe | 123 | 30 | -356* | 503 |
| Research and development expenses, net | 3,826 | 3,931 | 4,180* | 2,889 |
| General and administrative expenses | 2,766 | 2,534 | 2,452* | 2,509 |
| Operating loss | -6,506 | -6,350 | -6,578* | -5,198 |
| Financial income (expenses), net | - | - | -51* | - |
| Other financial income (expenses), net | -143 | 439 | - | -621 |
| Interest expenses | 231 | 229 | -1,486* | 217 |
| Total financial income (expenses), net | -374 | 210 | 1,435* | -838 |
| Loss before taxes | -6,880 | -6,140 | -5,143* | - |
| Tax benefit | -8 | -8 | -1* | - |
| Net loss | -6,872 | -6,132 | -5,142* | -6,036 |
| Net loss attributed to non-controlling interest | -329 | -282 | -205* | -154 |
| Net loss attributed to shareholders | -6,543 | -5,850 | -4,937 | -5,882 |
| Basic EPS | -0.71 | -0.65 | -0.684 | -1.08 |
| Diluted EPS | -0.71 | -0.65 | -0.684 | -1.08 |
| Basic Average Shares | 9,260,439 | 8,995,635 | 7,214,750 | 5,459,236 |
| Diluted Average Shares | 9,260,439 | 8,995,635 | 7,214,750 | 5,459,236 |
Pluri Inc. (PLUR)
Pluri Inc. (PLUR)